Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

147.31USD
10:48am EST
Change (% chg)

$0.45 (+0.31%)
Prev Close
$146.86
Open
$147.84
Day's High
$147.93
Day's Low
$146.75
Volume
429,389
Avg. Vol
1,898,821
52-wk High
$148.06
52-wk Low
$110.76

Latest Key Developments (Source: Significant Developments)

J&J says in Sept, co and Janssen were contacted by Texas and Colorado AG's offices
Thursday, 2 Nov 2017 04:33pm EDT 

Nov 2 (Reuters) - Johnson & Johnson :Johnson & Johnson - In September, co and Janssen Pharmaceuticals were contacted by the Texas and Colorado attorney general’s offices.Johnson & Johnson - co and Janssen Pharmaceuticals contacted on behalf of about 38 states regarding a multi-state attorney general investigation.Johnson & Johnson - The multi-state coalition served co and Janssen with subpoenas as part of the investigation related to opioids marketing practices.  Full Article

Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Halozyme Therapeutics Inc :Halozyme - ‍Janssen Biotech initiated first phase 3 clinical trial evaluating subcutaneous delivery of Darzalex with co's enhanze technology​.Halozyme Therapeutics Inc - will receive a $15 million milestone payment from Janssen following dosing of third patient in a phase 3 trial​.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 07:30am EDT 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

Johnson & Johnson says FDA approved 10 mg dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Johnson & Johnson -:FDA approves new 10 mg dosing for Xarelto® (rivaroxaban) to reduce the continued risk of venous thromboembolism (VTE).Janssen Pharmaceuticals says U.S. FDA approved 10 mg once-daily dose of Xarelto for reducing continued risk for recurrent venous thromboembolism​.  Full Article

Janssen Pharmaceutica says Phase 3 Amber study achieved its primary endpoint​
Wednesday, 25 Oct 2017 08:04am EDT 

Oct 25 (Reuters) - Johnson & Johnson :Investigational Darunavir-based single-tablet regimen shows positive results in previously untreated HIV patients in pivotal phase 3 Amber clinical trial.Janssen Pharmaceutica NV - Phase 3 Amber study achieved its primary endpoint​.  Full Article

Janssen receives two FDA approvals for SIMPONI ARIA for treatment of active psoriatic arthritis
Friday, 20 Oct 2017 04:23pm EDT 

Oct 20 (Reuters) - Johnson & Johnson :Janssen receives two U.S. FDA approvals for SIMPONI ARIA® (golimumab) for the treatment of adults with active psoriatic arthritis or active ankylosing spondylitis.‍Janssen Biotech says U.S. FDA approved SIMPONI ARIA for treatment of adults with active psoriatic arthritis or active ankylosing spondylitis​.  Full Article

Arcturus Therapeutics to collaborate with Johnson & Johnson
Thursday, 19 Oct 2017 07:00am EDT 

Oct 19 (Reuters) - Johnson & Johnson :Arcturus Therapeutics announces strategic collaboration with Johnson & Johnson Innovation to discover and develop RNA medicines.‍arcturus Therapeutics says has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals Inc​.‍arcturus Therapeutics Inc- agreement includes an option to expand into other infectious and respiratory diseases​.‍arcturus Therapeutics - deal was facilitated by Johnson & Johnson innovation center, in California​.‍arcturus Therapeutics - cos to work together to develop and commercialize nucleic acid-based drug products for treatment of Hepatitis B.Arcturus Therapeutics - ‍under agreement, Arcturus will receive an upfront cash payment, research and development support, pre-clinical, development, sales milestone payments​.  Full Article

J&J sets quarterly cash dividend of $0.84 per share
Thursday, 19 Oct 2017 06:50am EDT 

Oct 19 (Reuters) - Johnson & Johnson :Sets quarterly cash dividend of $0.84 per share.  Full Article

Johnson & Johnson Q3 earnings per share $1.37
Tuesday, 17 Oct 2017 06:40am EDT 

Oct 17 (Reuters) - Johnson & Johnson ::Johnson & Johnson reports 2017 third-quarter results.Q3 earnings per share $1.37.Q3 sales $19.7 billion versus I/B/E/S view $19.28 billion.Q3 earnings per share view $1.80 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.25 to $7.30.Q3 adjusted non-GAAP earnings per share $1.90 excluding items.Sees FY 2017 sales $76.1 billion to $76.5 billion.Qtrly ‍worldwide pharmaceutical sales of $9.7 billion for Q3 2017 represented an increase of 15.4% versus prior year​.Excluding net impact of acquisitions and divestitures, on operational basis, worldwide, domestic, international sales each increased 3.8% in quarter​.Worldwide medical devices sales of $6.6 billion for Q3 2017 represented an increase of 7.1% versus prior year​.Qtrly ‍worldwide consumer sales of $3.4 billion for Q3 2017 represented an increase of 2.9% versus prior year​.Qtrly worldwide Velcade sales $273‍​ million versus $290 million in Q2 2017.Qtrly worldwide Remicade sales $‍​1,647 million versus $1,530 million in Q2 2017.Qtrly worldwide Zytiga sales $669‍​ million versus $558 million in Q2 2017.Qtrly worldwide Invokana/Invokamet sales $265‍​ million versus $295 million in Q2.Third-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.9 billion​.Third-quarter 2017 net earnings included charge for after-tax special items of approximately $0.5 billion​.  Full Article

Cerveau Technologies announces research collaboration agreement with Janssen Pharmaceuticals
Monday, 16 Oct 2017 02:50pm EDT 

Oct 16 (Reuters) - Cerveau Technologies Inc: :Says announced a research collaboration agreement with Janssen Pharmaceuticals Inc for use of F-18MK-6240​ ‍​.Says collaboration is focused on using F-18MK-6240 as a biomarker in Janssen neurodegenerative disease research studies​.Says parties will collaborate on using F-18MK-6240 to diagnose and evaluate new treatments for neurodegenerative diseases in humans​.  Full Article

Deals of the day-Mergers and acquisitions

Jan 17 The following bids, mergers, acquisitions and disposals were reported by 1400 GMT on Wednesday: